This enrollment was completed ahead of schedule. The results from the trial are expected to be available in the second half of 2008. The company said that this Macroflux transdermal microprojection delivery system provides unique benefits, including convenient needle-free administration with room temperature stability for various therapeutic peptides, proteins, small molecules and vaccines.
Cory Zwerling, Zosano’s CEO and president, said: “Closing enrollment early is an important milestone for Zosano. This achievement reflects positively on physician and patient acceptance of our parathyroid hormone delivery system.”